Compass Therapeutics, Inc. is a high-risk Pharmaceuticals company based in the United States of America. Specializing in developing proprietary antibody therapeutics for treating solid tumors and hematological malignancies, Compass Therapeutics utilizes its unique ESG score to drive drug discovery. By leveraging its proprietary antibody discovery engine, the company identifies optimal combinations to engage the immune system. With a pipeline consisting of three key product candidates - CTX-009, CTX-471, and CTX-8371 - Compass Therapeutics is at the forefront of innovative biopharmaceutical research.